Stocks of Olema Pharmaceuticals and Others Decline Pre-Market

Author: Lucas Young Updated: 10-20-2025 08:30 AM

Market Trends and Stock Movements

On a promising note, U.S. stock futures showed resilience this morning, seeing an uptick with the Dow futures recording an increase of approximately 0.2% at the outset of trading.

Olema Pharmaceuticals Inc’s Market Performance

However, shares of Olema Pharmaceuticals Inc (NASDAQ: OLMA) experienced a severe downturn, plummeting by 18.3% to $7.64 in early pre-market trading. This significant drop followed the company’s disclosure of new findings from its Phase 1b/2 trial examining the efficacy of palazestrant in combination with ribociclib for treating ER+/HER2- metastatic breast cancer, as presented at a recent medical conference.

Other Notable Stock Movements

In addition to Olema Pharmaceuticals, several other stocks are facing declines in their pre-market sessions. Here’s a closer look at these stocks:

Concord Medical Services Holdings Ltd (NYSE: CCM) saw a staggering decrease of 24.4%, trading down to $4.15 after a troubling 6% dip on the prior Friday.
Addex Therapeutics Ltd – ADR (NASDAQ: ADXN) faced a decline of 15.6%, with shares priced at $9.23, following a previous day’s gain of 28%.
Exelixis Inc (NASDAQ: EXEL) also witnessed declines, slipping 8.3% to $36.00 post-announcement of their Phase 3 STELLAR-303 pivotal trial results, which evaluated zanzalintinib in conjunction with an immune checkpoint inhibitor in metastatic colorectal cancer.
Cellectis SA (NASDAQ: CLLS) dropped 7.3%, priced at $3.69 in the pre-market trading.
Alumis Inc (NASDAQ: ALMS) had a slight decline of 6.7%, with shares trading at $4.19.
Nanobiotix SA – ADR (NASDAQ: NBTX) fell 6.3% to $23.98 after a 4% decrease the previous Friday.
Genmab A/S – ADR (NASDAQ: GMAB) decreased by 4.1%, trading at $31.81, despite reporting promising results for its therapy Rinatabart Sesutecan in advanced endometrial cancer.
Taysha Gene Therapies Inc (NASDAQ: TSHA) experienced a decline of 4%, settling at $4.53.

Market Outlook

As we move forward in this trading session, it is crucial to closely monitor these companies as they navigate through market fluctuations. The data being released and the investor reactions to these trends will ultimately shape their performance in the upcoming days.

Frequently Asked Questions

What caused the drop in Olema Pharmaceuticals' stock price?

The drop occurred due to the announcement of Phase 1b/2 trial data regarding their treatment for metastatic breast cancer, which influenced investor confidence negatively.

How did other biotech stocks perform in pre-market trading?

Several biotech stocks, including Exelixis and Addex Therapeutics, also experienced declines, reflecting a broader trend in the market.

Are there any stocks that gained in this trading session?

While the article focuses on declining stocks, it's essential to look at market trends for potential gainers separately.

Why are investors concerned about pre-market trading?

Pre-market trading can be indicative of how stocks will perform during the main trading session, often influenced by overnight news and events.

What is the importance of the Phase 3 STELLAR-303 trial for Exelixis?

The trial results could significantly impact Exelixis's stock value and investor confidence, determining the future direction of their treatment in the market.

About The Author

Even at just 28 years old, Lucas Young has made a name for himself as a writer and financial expert. Lucas is a gifted communicator of difficult financial ideas and has written a number of well-received books and articles that appeal to both new and experienced investors. The financial world has come to rely on his perceptive analysis and useful counsel. Many people have been enabled to make wise investment decisions by Lucas's commitment to financial literacy and his ability to demystify the complexities of the market. Lucas is still dedicated to advising and teaching people on their financial journeys as he shares his knowledge.

Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.